entertainment -WSS

entertainment

author：fashion 2025-09-30 01:12:16 - browse：6738

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： A new initiative will help leaders fight the next pandemic

leisure time

WSS

Syphilis numbers in the United States reach record heights

Elevance PBM president out as customers face prescription chaos

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Venture capital firm's plans to take over Akron hospital face hurdles

Medicare Advantage insurers face 0.2% cut to 2025 payments

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Wikipedia

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

White House pharmacy plagued with problems, investigation finds

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stopping antidepressants leads to symptoms for 1 in 6 patients

Novavax promises a turnaround & Lilly roils the obesity market

Elevance PBM president out as customers face prescription chaos

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana’s losses in Medicare Advantage tank its stock

United colonoscopy coverage change 'may cost lives,' doctors say

The most pressing bird flu mysteries scientists want answered

entertainment

Elevance PBM president out as customers face prescription chaos

The most pressing bird flu mysteries scientists want answered

Eli Lilly’s Zepbound improved liver scarring in mid

BD to buy Edwards patient monitoring unit for $4.2 billion

Senators tussle over abortion against the backdrop of a presidential campaign

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

knowledge

Wikipedia

leisure time

hotspot